美国的生物相似药市场:各级产品，各适应症，各流通管道，各地区，机会，预测，2018年～2032年

美国生物相似药市场规模预计将从2024年的95.2亿美元成长至2032年的291.2亿美元，在2025-2032年的预测期内，复合年增长率为15%。美国生物相似药市场的发展受到医疗保健成本上涨以及对可负担治疗方案的需求的驱动，尤其是在肿瘤和慢性病领域。可互换性认定和自动替代等监管改革正在加速生物相似药的普及。同时，主要参与者不断扩展产品线并采取策略性举措，正在增强其市场影响力和患者可及性。

本报告提供美国的生物相似药市场相关调查，提供市场概要，以及各级产品，各适应症，各流通管道，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 美国的关税的影响

第4章 摘要整理

第5章 美国生物相似药市场预测，2018年～2032年

• 市场规模分析与预测
• 市场占有率分析与预测
  • 各级产品
    • 单株抗体
    • 重组的荷尔蒙
    • 免疫调节剂
    • 抗发炎剂
    • 其他
  • 各适应症
    • 肿瘤学
    • 生长激素缺乏症
    • 血液疾病
    • 慢性疾病及自体免疫疾病
    • 感染疾病
    • 其他
  • 各流通管道
    • 医院
    • 癌症照护中心
    • 其他
  • 各地区
    • 西北部
    • 西南部
    • 西部
    • 东南部
    • 中西部
  • 各企业市场占有率分析(前五名公司以及其他- 各金额，2024年)
• 2024年的市场地图分析

第6章 需求供给分析

第7章 价值链分析

第8章 波特的五力分析

第9章 大环境分析

第10章 价格分析

第11章 市场动态

• 市场促进因素
• 市场课题

第12章 市场趋势与发展

第13章 法规结构和革新

• 法规当局的认证
• 临床试验

第14章 专利的形势

第15章 案例研究

第16章 竞争情形

• 前五名市场领导的竞争矩阵
• 前五名参与企业的SWOT分析
• 前10名市场主要企业的形势
  • Novartis AG
  • Pfizer, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Amgen, Inc.
  • Eli Lilly and Company
  • Celltrion Inc.
  • Teva Pharmaceuticals, Inc.
  • Viatris Inc.
  • Samsung Bioepis Co., Ltd.
  • Bristol-Myers Squibb Company

第17章 策略性建议

第18章 关于调查公司·免责声明

United States biosimilars market is projected to witness a CAGR of 15% during the forecast period 2025-2032, growing from USD 9.52 billion in 2024 to USD 29.12 billion in 2032. The U.S. biosimilars market is being propelled by rising healthcare costs and demand for affordable treatment options, especially in oncology and chronic conditions. Regulatory reforms such as interchangeability designations and automatic substitution laws are accelerating biosimilar uptake. Simultaneously, expanding product pipelines and strategic initiatives by key players strengthen market presence and patient access.

Increasing Healthcare Cost Burden Driving Demand for Cost-Effective Biosimilars

The increasing expenses associated with biologic therapies in the United States have heightened the need for more cost-effective biosimilars. As the healthcare system faces challenges from the prevalence of chronic diseases, an aging population, and inflationary pressures, biosimilars present a viable alternative that maintains efficacy while being more affordable. Typically, biosimilars are introduced to the market at prices 15-35% lower than their reference biologics, which significantly alleviates treatment costs for both patients and healthcare providers. Their adoption is especially prominent in high-cost therapeutic fields such as oncology and autoimmune diseases. Additionally, the growing emphasis on value-based care by payers and the strategic placement of biosimilars in formularies are further promoting their use. Government initiatives, including the Biologics Price Competition and Innovation Act (BPCIA), continue to facilitate quicker approvals and enhance market competition. In December 2023, Pfizer reported a 43% year-over-year growth in its biosimilars portfolio in the U.S., largely driven by oncology biosimilars like ZIRABEV and NYVEPRIA. This momentum underscores how healthcare systems and providers are embracing biosimilars to enhance access, reduce drug expenditure, and improve long-term sustainability.

Expanding Oncology Indications Accelerating Market Penetration

Biosimilars are rapidly gaining popularity in oncology, a crucial sector of the U.S. pharmaceutical industry. The expiration of patents for several leading monoclonal antibodies (mAbs), including trastuzumab, rituximab, and bevacizumab, has created significant opportunities for biosimilar producers. Given that oncology treatment regimens are generally long-term and costly, they represent an ideal candidate for biosimilar replacement. The acceptance of biosimilars in clinical settings has grown as oncologists become more assured of their safety and efficacy, supported by real-world data and endorsements from the FDA. Furthermore, healthcare systems and cancer treatment centers are promoting the use of biosimilars by incorporating them into their formularies and treatment guidelines. For instance, in October 2024, Teva Pharmaceuticals and mAbxience announced an expanded collaboration agreement for the development of an anti-PD1 oncology biosimilar candidate. These advancements highlight the strategic importance of oncology in shaping biosimilar growth. The continuous pipeline of new biosimilars targeting oncologic indications is expected to further strengthen this trend, creating a ripple effect across other specialty therapeutic areas.

Supportive Regulatory Reforms and Regional Initiatives Boosting Market Expansion

The U.S. FDA has optimized the biosimilar approval process through the BPCIA, creating a more advantageous regulatory landscape for biosimilar developers. These modifications have led to shorter approval periods, enhanced interchangeability designations, and heightened trust among prescribers. On a regional level, states are enacting automatic substitution laws that permit pharmacists to replace interchangeable biosimilars without needing physician consent, thereby further promoting adoption. Additionally, the FDA's educational initiatives, including the 'Biosimilars Action Plan,' are significantly contributing to the enhancement of awareness among providers and patients. On April 14, 2025, Celltrion declared that the FDA has granted its adalimumab-aaty (marketed as YUFLYMA) an interchangeable designation. This biosimilar is based on adalimumab (known as Humira). The FDA has approved adalimumab-aaty as a high-concentration (100mg/mL) and citrate-free formulation of the reference biologic adalimumab for the treatment of various inflammatory conditions. Regional expansion is notably apparent in states with significant Medicaid participation, where biosimilars are regarded as a cost-effective alternative. With increasing regulatory backing, it is anticipated that biosimilar manufacturers will gain enhanced market access, higher adoption rates, and diminished resistance to pricing.

Future Market Scenario (2025-2032F)

The U.S. biosimilars market is set for substantial expansion in the coming decade, fueled by the expiration of patents for major biologics, rising demands to lower healthcare expenses, and supportive regulatory changes that facilitate biosimilar approvals and their interchangeability. The growing range of therapeutic uses for biosimilars in fields such as oncology, autoimmune disorders, and endocrinology will further enhance demand. As healthcare providers and payers gain greater confidence in the safety and effectiveness of biosimilars, a wider acceptance in various healthcare environments, including hospitals, cancer treatment centers, and specialized clinics-is anticipated. Moreover, increased investments from leading pharmaceutical firms and greater patient awareness will enhance market penetration. By the year 2030, the biosimilars market is expected to play a pivotal role in transforming specialty drug pricing and improving access to essential therapies for patients in the United States.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of biosimilars and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, Teva Pharmaceuticals and Alvotech have officially announced the launch of Selarsdi (ustekinumab-aekn) injection in the United States, which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). This medication is approved for treating Crohn's disease, pediatric plaque psoriasis, pediatric psoriatic arthritis, plaque psoriasis, psoriatic arthritis, and ulcerative colitis. This represents the second biosimilar introduced in the country as a result of the strategic partnership between the two companies.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. United States Biosimilars Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product Class
    • 5.2.1.1. Monoclonal Antibodies
      • 5.2.1.1.1. Adalimumab
      • 5.2.1.1.2. Infliximab
      • 5.2.1.1.3. Rituximab
      • 5.2.1.1.4. Trastuzumab
      • 5.2.1.1.5. Others
    • 5.2.1.2. Recombinant Hormones
      • 5.2.1.2.1. Insulin
      • 5.2.1.2.2. Erythropoietin
      • 5.2.1.2.3. Others
    • 5.2.1.3. Immunomodulators
    • 5.2.1.4. Anti-Inflammatory Agents
    • 5.2.1.5. Others
  • 5.2.2. By Indication
    • 5.2.2.1. Oncology
    • 5.2.2.2. Growth Hormone Deficiency
    • 5.2.2.3. Blood Disorders
    • 5.2.2.4. Chronic and Autoimmune Disorders
    • 5.2.2.5. Infectious Diseases
    • 5.2.2.6. Others
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospitals
    • 5.2.3.2. Cancer Care Centers
    • 5.2.3.3. Others
  • 5.2.4. By Region
    • 5.2.4.1. Northwest
    • 5.2.4.2. Southwest
    • 5.2.4.3. West
    • 5.2.4.4. Southeast
    • 5.2.4.5. Midwest
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product Class
  • 5.3.2. By Indication
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Clinical Trials

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novartis AG
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Pfizer, Inc.
  • 16.3.3. Dr. Reddy's Laboratories Ltd.
  • 16.3.4. Amgen, Inc.
  • 16.3.5. Eli Lilly and Company
  • 16.3.6. Celltrion Inc.
  • 16.3.7. Teva Pharmaceuticals, Inc.
  • 16.3.8. Viatris Inc.
  • 16.3.9. Samsung Bioepis Co., Ltd.
  • 16.3.10. Bristol-Myers Squibb Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Biosimilars Market, By Value, In USD Billion, 2018-2032F
• Figure 2. United States Biosimilars Market Share (%), By Product Class, 2018-2032F
• Figure 3. United States Biosimilars Market Share (%), By Indication, 2018-2032F
• Figure 4. United States Biosimilars Market Share (%), By Distribution Channel, 2018-2032F
• Figure 5. United States Biosimilars Market Share (%), By Region, 2018-2032F
• Figure 6. By Product Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 7. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 8. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 9. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024